More than 500 million patients worldwide suffer from eye diseases such as macular degeneration and diabetic retinopathy, and up to 30 percent of patients refuse corresponding treatments because these previously required direct injection into the eye.
In comparison to conventional eye injections, this non-invasive procedure is expected to have the potential to save up to 80 percent of time needed in drug administration.
Opharmic CEO, Langston Suen, says “Eye patients are increasingly looking for non-invasive treatment options at affordable pricing. Our ultrasound drug delivery system delivers therapeutics in the eye through the sclera by ultrasound-induced microstreaming, in which the drug molecules can diffuse into target eye tissue.”
CeramTec's specialised sensor and transducer expertise enabled the fine-tuning of Opharmic's ultrasonic transducer design in order to achieve the required consistency and performance.
Opharmic’s novel drug delivery device was last year recognised as the winner of the 2021 Asia Pacific Accelerator program. The program is run by MedTech Innovator, one of the largest accelerators of Life Science companies in the world, and the Asia Pacific Medical Technology Association (APACMed).
